ASCIMINIB | ASCIMINIB | ATC L01EA06
ANTINEOPLASTIC ABL1 KINASE INHIBITOR TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) INHIBITS THE ABL1 KINASE ACTIVITY OF THE BCR-ABL1 FUSION PROTEIN | ORAL | Cmax 12.5 MICROMOLAR Tmax 2.5 HOUR VD 151 LITER PPB 97 PERCENT Cl 4.1 LITER / HOUR HT 9 HOUR | ABL1 KINASE PDB 5MO4 (ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB) LIGAND CODE = AY7 (link to the list of PDB complexes) Download experimental 3D coordinates of AY7 with added hydrogens | Tyrosine-protein kinase ABL1 UNIPROT P00519 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |